Cargando…
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
Autores principales: | D’Alessio, A., Del Poggio, P., Bracchi, F., Cesana, G., Sertori, N., Di Mauro, D., Fargnoli, A., Motta, M., Giussani, C., Moro, P., Vitale, G., Giacomini, M., Borra, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654848/ https://www.ncbi.nlm.nih.gov/pubmed/33173161 http://dx.doi.org/10.1038/s41375-020-01087-z |
Ejemplares similares
-
On Cancer, COVID-19, and CT Scans: A Monocentric Retrospective Study
por: Martini, Francesca, et al.
Publicado: (2020) -
Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report
por: Meazza Prina, Marco, et al.
Publicado: (2021) -
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018) -
Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020) -
P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
por: Abraham, P., et al.
Publicado: (2022)